ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.

ADVM Adverum Biotechnologies Inc

10,43
0,43 (4,30%)
04 Mai 2024 - Geschlossen
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Adverum Biotechnologies Inc ADVM NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
0,43 4,30% 10,43 06:00:01
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
10,10 10,00 10,69 10,43 10,00
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
03.5.202414:00GLOBEAdverum Biotechnologies to Participate in Upcoming May..
25.4.202422:05GLOBEAdverum Biotechnologies to Present LUNA 26-week Phase 2..
18.3.202421:05GLOBEAdverum Biotechnologies Reports Fourth Quarter and Full Year..
04.3.202422:40EDGAR2Form S-3 - Registration statement under Securities Act of..
28.2.202422:05GLOBEAdverum Biotechnologies to Participate in the TD Cowen 44th..
22.2.202421:47EDGAR2Form SC 13G - Statement of acquisition of beneficial..
21.2.202421:39EDGAR2Form D - Notice of Exempt Offering of Securities
15.2.202422:17EDGAR2Form SC 13G - Statement of acquisition of beneficial..
15.2.202402:26EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14.2.202422:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14.2.202422:30EDGAR2Form SC 13G - Statement of acquisition of beneficial..
14.2.202422:27EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14.2.202422:05EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
12.2.202414:00GLOBEAdverum Biotechnologies to Participate in the Oppenheimer..
09.2.202423:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09.2.202417:41EDGAR2Form SC 13G - Statement of acquisition of beneficial..
08.2.202414:45EDGAR2Form 8-K - Current report
08.2.202413:00GLOBEAdverum Biotechnologies Announces Positive Preliminary..
06.2.202422:47EDGAR2Form 8-K - Current report
05.2.202423:03EDGAR2Form 8-K - Current report
05.2.202413:45GLOBEAdverum Biotechnologies Announces $127.5 Million Private..
01.2.202423:30GLOBEAdverum Biotechnologies will Host Webcast to Review LUNA..
29.1.202414:00GLOBEAdverum Biotechnologies Appoints Romuald Corbau, Ph.D. as..
08.12.202322:11EDGAR2Form 8-K - Current report
07.12.202322:05GLOBEAdverum Biotechnologies to Present LUNA Preliminary Efficacy..
04.12.202322:09EDGAR2Form 8-K/A - Current report: [Amend]
28.11.202322:05GLOBEAdverum Biotechnologies to Participate in the Evercore ISI..
09.11.202322:08EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09.11.202322:07EDGAR2Form 8-K - Current report
09.11.202322:05GLOBEAdverum Biotechnologies Reports Third Quarter 2023 Financial..
07.11.202301:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07.11.202301:52EDGAR2Form 3 - Initial statement of beneficial ownership of..
06.11.202322:10EDGAR2Form 8-K - Current report
06.11.202314:00GLOBEAdverum Biotechnologies Appoints C. David Nicholson, Ph.D...
04.11.202322:54GLOBEAdverum Biotechnologies Announces 3-Year Efficacy and Safety..
26.9.202322:05GLOBEAdverum Biotechnologies Announces Positive Aflibercept..
21.9.202322:05GLOBEAdverum Biotechnologies to Participate in Upcoming Investor..
19.9.202300:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05.9.202322:05GLOBEAdverum Biotechnologies to Participate in the H.C...
21.8.202322:05GLOBEAdverum Biotechnologies Appoints Andrew Ramelmeier, Ph.D. as..
14.8.202314:00GLOBEAdverum Biotechnologies to Participate in the H.C...
10.8.202322:11EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10.8.202322:09EDGAR2Form 8-K - Current report
10.8.202322:05GLOBEAdverum Biotechnologies Completes Enrollment of Phase 2 LUNA..
04.8.202322:18EDGAR2Form 8-K - Current report
24.7.202322:16EDGAR2Form SC 13G - Statement of acquisition of beneficial..
12.6.202314:00GLOBEAdverum Biotechnologies Grants License to Ray Therapeutics..
02.6.202314:00GLOBEAdverum Biotechnologies to Participate in the Jefferies..
25.5.202312:30GLOBEAdverum Biotechnologies Announces New Executive Leadership..
18.5.202315:00GLOBEAdverum Biotechnologies Introduces an Intravitreal Gene..

Kürzlich von Ihnen besucht

Delayed Upgrade Clock